Related references
Note: Only part of the references are listed.Effect of Physical Activity Level on Biomarkers of Inflammation and Insulin Resistance Over 5 Years in Outpatients With Coronary Heart Disease (from the Heart and Soul Study)
Jennifer L. Jarvie et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program
Benoit J. Arsenault et al.
ATHEROSCLEROSIS (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
CIRCULATION (2014)
2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Robert H. Eckel et al.
CIRCULATION (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
The effect of insulin on circulating PCSK9 in postmenopausal obese women
Zuhier Awan et al.
CLINICAL BIOCHEMISTRY (2014)
Mechanism of action of anti-hypercholesterolemia drugs and their resistance
Vishvanath Tiwari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9
Kevin Ly et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease
Xiao-Qing Lian et al.
PREVENTIVE MEDICINE (2014)
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
Emile Levy et al.
ATHEROSCLEROSIS (2013)
Diagnosis and treatment of familial hypercholesterolaemia
G. Kees Hovingh et al.
EUROPEAN HEART JOURNAL (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome
Caroline Richard et al.
BRITISH JOURNAL OF NUTRITION (2012)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
Physical Activity and Inflammatory Markers Over 10 Years Follow-Up in Men and Women From the Whitehall II Cohort Study
Mark Hamer et al.
CIRCULATION (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
PCSK9 Inhibition The Next Statin?
Robert A. Vogel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Nabil G. Seidah et al.
PLOS ONE (2012)
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
Janice Mayne et al.
CLINICAL CHEMISTRY (2011)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention
Philippe Meyer et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2010)
A catalogue of reporting guidelines for health research
I. Simera et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Effects of aerobic and strength-based training on metabolic health indicators in older adults
Raul A. Martins et al.
LIPIDS IN HEALTH AND DISEASE (2010)
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2009)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Annexins - unique membrane binding proteins with diverse functions
U Rescher et al.
JOURNAL OF CELL SCIENCE (2004)
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease -: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)
PD Thompson et al.
CIRCULATION (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
